Cefuroxime Sodium for Injection

This product is a compound preparation composed of guaifenesin, pseudoephedrine hydrochloride, dextromethorphan hydrobromide and acetaminophen. Among them, acetaminophen is an antipyretic and analgesic, which mainly produces analgesic effect by inhibiting prostaglandin synthesis; guaifenesin is a nausea and expectorant, which stimulates the gastric mucosa, causes mild nausea and reflexively increases the secretion of respiratory glands, dilutes sputum and makes it easier to cough up; pseudoephedrine hydrochloride is an adrenergic drug that can constrict nasal mucosal blood vessels and relieve nasal congestion and runny nose symptoms; dextromethorphan hydrobromide is a central antitussive drug that can inhibit the cough center in the medulla oblongata to produce an antitussive effect. The general therapeutic dose does not inhibit breathing, and long-term use is non-addictive and non-tolerant.

Cefuroxime Sodium

This product is white or slightly yellowish white crystalline powder, odorless or with a slight peculiar odor, easily soluble in water, less soluble in methanol, and almost insoluble in ethanol or ether.

This product can be used for the following infections caused by the above-mentioned sensitive bacteria: 1. Respiratory system infections: tonsillitis, peritonsillar abscess, bronchitis, bronchiolitis, bronchiectasis (infection), secondary infection of chronic respiratory diseases, pneumonia, pulmonary suppuration. 2. Urinary system infections: pyelonephritis, cystitis. 3. Abdominal infections: cholecystitis, cholangitis, peritonitis. 4. Pelvic infections: pelvic peritonitis, adnexitis, intrauterine infection, pelvic dead cavity inflammation, parametrial tissue inflammation. 5. Sepsis.

This product is only for intravenous injection or intravenous drip. Intravenous injection: During intravenous injection, each 1g (titer) of the drug can be dissolved with 20ml of water for injection, 5%-10% glucose injection or 0.9% sodium chloride injection. Intravenous drip: During intravenous drip, each 1g (titer) of the drug can be dissolved with 100-500ml of water for injection, 5%-10% glucose injection or 0.9% sodium chloride injection, and drip for 1-2 hours. The recommended common dose is: 1g (titer) each time for adults, twice a day, which can be increased or decreased appropriately according to age and symptoms. For sepsis, refractory or severe infections, it can be increased to 6g (titer) per day, divided into 3-4 doses; children are measured by weight 20mg (titer)/kg each time, 3-4 times a day. This product should be prepared when it is used and used as soon as possible after dissolution.

1. Allergic reactions are more common with symptoms such as rash, fever, and itching; anaphylactic shock is occasionally seen. 2. Gastrointestinal symptoms such as loss of appetite, nausea, vomiting, and diarrhea are more common; pseudomembranous colitis is occasionally seen. 3. Liver A small number of patients may experience jaundice and temporary liver function abnormalities (increased GOT, GPT, AL-P, and blood bilirubin, etc.) after taking the drug. 4. Kidney A small number of patients may experience oliguria, proteinuria, and abnormal renal function [increased creatinine (Jaffe method), urea nitrogen, etc.] after taking the drug. 5. Blood A small number of patients may experience decreased platelet, red blood cell, and granulocyte counts or increased eosinophilia, prolonged prothrombin time, etc. after taking the drug; pancytopenia may occur occasionally. 6. Dual infection Long-term use of the drug may cause dysbacteriosis, secondary infection, and occasionally stomatitis and candidiasis. 7. Other small numbers of patients may experience symptoms of vitamin B deficiency and vitamin K deficiency after long-term use of the drug; and occasionally general fatigue.

It is contraindicated in patients with a history of allergic reactions to cefuroxime or cephem antibiotics.

This product cannot be used in combination with aminophylline or pyridoxal phosphate because it will reduce potency or color. It should not be used in combination with fursultiamine, lipoic acid, hydrocortisone sodium succinate and adenosylcobalamin because it will change color after a while. It should be used as soon as possible after combination. It may increase renal toxicity when used in combination with diuretics (such as furanilamide). Animal experiments have confirmed that this product affects alcohol metabolism, increases blood acetaldehyde concentration, and shows a disulfiram-like effect. Therefore, alcohol should be avoided during or after medication.

Keep in a dark and airtight place in a cool and dry place. Validity period: two years

2.0g (based on C16H21N7O7S3)

Qilu Pharmaceutical Co., Ltd.

• Founded in:

  1992-08-21

• Address:

  No. 317, Xinluo Street, High-tech Zone, Jinan City, Shandong Province

• Tax NO.:

  91370000614073351Q

• Registered Funds:

  600 million yuan

• Website:

  Log in to view

• Email:

  Log in to view